Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.

Abstract

OBJECTIVES:

The purpose of this study was to compare the efficacy and safety of drug-eluting beads transarterial chemoembolization plus camrelizumab (D-TACE-C) with conventional transarterial chemoembolization plus camrelizumab (C-TACE-C) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).

MATERIALS AND METHODS:

This was a retrospective study that evaluated the consecutive medical records of patients with unresectable HCC who had undergone D-TACE-C or C-TACE-C from April 2020 to August 2021. Efficacy of treatment was evaluated using tumor response, progression-free survival (PFS) and survival rates. The adverse events were recorded.

RESULTS:

A total of 54 patients were included in this study, including 27 patients who had received D-TACE-C treatment, and 27 patients who had received C-TACE-C treatment. The median PFS and DCR in the D-TACE-C group were significantly longer than those for the C-TACE-C group (PFS: 10 vs. 3 months, P=.017; DCR: 70.4% vs. 40.7%, P = .028). Cox regression analysis showed that D-TACE-C was the only protective factor for PFS. The 6-month and 12-month survival rates in D-TACE-C group and C-TACE-C group were 85.2% versus 79.4% (P = .646) and 65.2% versus 65.1% (P = .903), respectively. Reactive cutaneous capillary endothelial proliferation was the most common adverse event associated with the treatment. There was no significant difference in the adverse events related to TACE and camrelizumab between the two groups. No treatment-related deaths occurred in this study.

CONCLUSIONS:

D-TACE-C is a safe and well-tolerated treatment, and may produce better PFS and tumor response in patients with unresectable HCC than C-TACE-C.

• Authors: Yanqiao Ren, Yusheng Guo, Lei Chen, Tao Sun, Weihua Zhang, Bo Sun, Licheng Zhu, Fu Xiong, Chuansheng Zheng
• Journal: Cancer control : journal of the Moffitt Cancer Center (Cancer Control) 2022 Jan-Dec Vol. 29 Pg. 10732748221076806 ISSN: 1526-2359 [Electronic] United States
• PMID: 35343254 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• camrelizumab

Topics

• Antibodies, Monoclonal, Humanized
• Carcinoma, Hepatocellular (drug therapy)
• Chemoembolization, Therapeutic
• Humans
• Liver Neoplasms (drug therapy)
• Retrospective Studies